Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).
David Raymond Ferry
Honoraria - Sanofi
Alberto F. Sobrero
Consultant or Advisory Role - Amgen; Bayer; Merck; Roche; Sanofi
Honoraria - Amgen; Bayer; Celgene; Roche; Sanofi
Roberto Bordonaro
No relevant relationships to disclose
Salvatore Siena
No relevant relationships to disclose
Filippo Pietrantonio
Consultant or Advisory Role - Merck; Roche; Sanofi
Honoraria - Roche
Stefan Bauer
No relevant relationships to disclose
Julien Taïeb
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Pascale Garreau-Laporte
Employment or Leadership Position - Sanofi
Sandrine Brette
Employment or Leadership Position - Sanofi
Emmanuelle Dochy
Employment or Leadership Position - Sanofi
Gérard Lledo
No relevant relationships to disclose